Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mike M who wrote (2896)	10/28/2000 12:54:43 PM
From: Mad2	Read Replies (2) \| Respond to of 5582

Mike, the point is GUMM's share price has priced in sucess in may of the "potential" products that have been discussed here, including ZICAM. I think you must admit the results with ZICAM have been modest to date delivering little to the bottom line (of GUMM shareholders that is). Subtract from the bottom line the effect of warrants and insider profit (read 2.2 mil in net compensation) and the results look a bit worse, not to mention the dilutive effect of the new shares. At some point the share price of GUMM will head towards its intrinic value (read valuation based on future cash flow) which could be quite a bit lower than the current level (see QGLY for a read on how that might look). Mad2